BG Medicine, Inc.

Beyond Genomics Appoints Stephen Martin as Senior Vice President and Chief Technical Officer

Beyond Genomics Appoints Stephen Martin as Senior Vice President and Chief Technical Officer

June 15, 2004

Waltham, Mass. - June 15, 2004--Beyond Genomics, Inc. (BG) today announced that Stephen A. Martin, PhD, has joined the Company as Senior Vice President and Chief Technical Officer. Dr. Martin joins BG from Applied Biosystems and brings over 23 years' experience in life science research. At BG, Dr. Martin will be responsible for the continued development and integration of the Company's Molecular Systems Biology platforms.

e-Dialog, Inc.

e-Dialog supports Sender-ID authentication; Supports new industry standards to fight fraudulent e-mail

e-Dialog supports Sender-ID authentication; Supports new industry standards to fight fraudulent e-mail

June 17, 2004

LEXINGTON, MA - June 17, 2004 - e-Dialog, the precision e-mail marketing innovator, today announced that they are aggressively beta testing their solutions that comply with Sender-ID authentication technologies and expect to be in full release in the next few weeks. Sender-ID is the combined technologies of POBox.com founder Meng Weng Wong's SPF and Microsoft's Caller-ID programs. e-Dialog has adopted these solutions to ensure maximum deliverability for our clients and to help the industry continue its fight against fraudulent e-mail.

Color Kinetics

Color Kinetics Announces Pricing of Initial Public Offering

Color Kinetics Announces Pricing of Initial Public Offering

June 22, 2004

Boston, MA - June 22, 2004 - Color Kinetics Incorporated (Nasdaq: CLRK) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at $10 per share. All of the shares are being offered by Color Kinetics. Color Kinetics' common stock is expected to begin trading on the Nasdaq National Market on June 22, 2004 under the symbol "CLRK."

Affinnova, Inc.

Affinnova, Inc. Appoints Procter & Gamble Veteran Mark F. Schar to Executive Board

Affinnova, Inc. Appoints Procter & Gamble Veteran Mark F. Schar to Executive Board

June 29, 2004

WALTHAM, Mass.--(BUSINESS WIRE)--June 29, 2004 -- Affinnova, Inc., which harnesses the science of evolution to optimize concepts, products and brands for consumer-focused companies, today announced the appointment of Mark F. Schar to its Executive Board. Mr. Schar, a corporate leader with over 25 years of International business development and consumer and market knowledge experience at Procter & Gamble, will assist in guiding Affinnova's strategic growth initiatives.

Morphotek, Inc.

Protein Design Labs and Morphotek Announce Broad, Multi-year Research Cross-license and Commercialization Agreement

Protein Design Labs and Morphotek Announce Broad, Multi-year Research Cross-license and Commercialization Agreement

July 19, 2004

Fremont, Calif., and Exton, PA, July 19, 2004 - Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) and Morphotek, Inc. today announced a broad, multi-year research and commercialization agreement, providing PDL access to Morphotek's MORPHODOMA® and Suppressor of Immunoglobulin Production (SIP) technology, and Morphotek access to PDL's technology for antibody humanization.

BG Medicine, Inc.

Beyond Genomics Announces Research and Development Advisory Board Lead by Co-chairs Arnold Levine, PhD and Jeffrey Friedman, MD, PhD

Beyond Genomics Announces Research and Development Advisory Board Lead by Co-chairs Arnold Levine, PhD and Jeffrey Friedman, MD, PhD

July 20, 2004

Waltham, Mass. - July 20, 2004 - Beyond Genomics, Inc. today announced the formation of a Research and Development Advisory Board comprised of leading scientists with broad experience in the study of human disease, and the discovery and development of pharmaceutical products. Arnold Levine, PhD and Jeffrey Friedman, MD, PhD are co-chairs of the board.

Black Duck Software, Inc.

Black Duck Software Secures $5 Million in Series A Financing

Black Duck Software Secures $5 Million in Series A Financing

July 26, 2004

Flagship Ventures and General Catalyst Partners co-lead Investment in Leading IP Risk Management and Mitigation Solutions Company

Waltham, Mass., July 26, 2004 - Black Duck Software, a leading provider of services that enable vendors and enterprises to manage software intellectual property (IP), today announced the closing of a $5 million round of Series A funding co-led by Flagship Ventures and General Catalyst Partners.

Affinnova, Inc.

Affinnova, Inc. Raises $4.5 Million in C Round from Sherbrooke Capital and Flagship Ventures

Affinnova, Inc. Raises $4.5 Million in C Round from Sherbrooke Capital and Flagship Ventures

August 17, 2004

Capital investment to accelerate market penetration, extend technology leadership and build operational capabilities to support growing industry adoption of IDEA(TM) Technology

Selventa

Genstruct and Berlex Biosciences Collaborate on Breast Carcinoma Research

Genstruct and Berlex Biosciences Collaborate on Breast Carcinoma Research

September 15, 2004

CAMBRIDGE, Mass., September 15, 2004 - Genstruct Inc., a knowledge-driven discovery company, announced today that it has entered into an agreement with Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), to characterize the regulatory mechanisms for breast cancer. The goal is to uncover the causal mechanisms for the initiation of breast cancer to better understand the genes, proteins and metabolites that play crucial roles in the development of this disease.

Adnexus Therapeutics

Compound Therapeutics and Abbott Laboratories Enter into Technology License Agreement for Drug Discovery

Compound Therapeutics and Abbott Laboratories Enter into Technology License Agreement for Drug Discovery

September 29, 2004

WALTHAM, Mass., Sept. 29 /PRNewswire/ -- Compound Therapeutics, a Massachusetts-based biotechnology company, announced today that they have entered into a license agreement with Abbott Laboratories granting Abbott non- exclusive rights to use Compound Therapeutics' PROfusion(TM) technology and certain antibody libraries. PROfusion is an in vitro display technology for the selection and rapid optimization of high-affinity antibodies and other binding proteins.